FDA-cleared profile

MammoScreen® (4)

Therapixel · Mammography/DBT · FDA-cleared (510(k))

Authorized purpose: Identifies calcifications, masses, asymmetries and architectural distortions on compatible FFDM or DBT screening examinations; it is not a standalone diagnostic device.

Clinical role
Concurrent reading and reporting aid that outputs graphical marks of soft-tissue lesion or calcification findings on mammograms with level of suspicion scores and lesion type, used by radiologists as complementary information; the interpreting medical professional remains the sole decision-maker.
Images and patients
Mammography/DBT · Breast
Key limitation
Keep in mind: Physicians must review the full examination and must not base management solely on the output.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Identifies calcifications, masses, asymmetries and architectural distortions on compatible FFDM or DBT screening examinations; it is not a standalone diagnostic device.
  • Which images or clinical context are in scope?Modality: Mammography/DBT Anatomy or clinical context: Breast Input: Compatible FFDM or DBT screening exams; the cleared modification adds Hologic Envision support.
  • Who uses it?Intended users: Physicians interpreting screening mammograms.
  • What does the software produce?Output: Finding marks and finding-, breast- and case-level scores; dedicated user interface/viewer, DICOM Secondary Capture and DICOM Structured Report outputs.
  • What is its most important limitation?Key limitation: Physicians must review the full examination and must not base management solely on the output.

Clinical takeaway. Clinical role: Identifies calcifications, masses, asymmetries and architectural distortions on compatible FFDM or DBT screening examinations; it is not a standalone diagnostic device.

Evidence takeaway. Evidence from the reviewed source record: Standalone comparison used 1,475 patients and 2,950 paired DBT studies; the regulatory summary reports AUC and localization endpoints for this specific compatibility evaluation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Identifies calcifications, masses, asymmetries and architectural distortions on compatible FFDM or DBT screening examinations; it is not a standalone diagnostic device.
  • Exact FDA submission
  • Checked 2026-09-05
Workflow role
Concurrent reading and reporting aid that outputs graphical marks of soft-tissue lesion or calcification findings on mammograms with level of suspicion scores and lesion type, used by radiologists as complementary information; the interpreting medical professional remains the sole decision-maker.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "MammoScreen® 4 is a concurrent reading and reporting aid for physicians interpreting mammograms." … "Output of the device includes graphical marks of findings as soft-tissue lesions or calcifications on mammograms along with their level of suspicion scores. The lesion type is characterized as mass/asymmetry, distortion, or calcifications for each detected finding.". Read from the exact FDA decision document on 2026-11-14.

Required input
Compatible FFDM or DBT screening exams; the cleared modification adds Hologic Envision support.
  • Exact FDA submission
  • Checked 2026-09-05
Output and clinician action
Finding marks and finding-, breast- and case-level scores; dedicated user interface/viewer, DICOM Secondary Capture and DICOM Structured Report outputs.
  • Exact FDA submission
  • Checked 2026-09-05
Care setting
Adult
  • Exact FDA submission
  • Checked 2026-09-01

Patient-population text reported in the exact-submission ACR model card; institutional setting may still require vendor confirmation.

Intended users
Physicians interpreting screening mammograms.
  • Exact FDA submission
  • Checked 2026-09-05
Limitations
Physicians must review the full examination and must not base management solely on the output.
  • Exact FDA submission
  • Checked 2026-09-05
Evidence summary
Standalone comparison used 1,475 patients and 2,950 paired DBT studies; the regulatory summary reports AUC and localization endpoints for this specific compatibility evaluation.
  • Exact FDA submission
  • Checked 2026-09-05

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Standalone comparison used 1,475 patients and 2,950 paired DBT studies; the regulatory summary reports AUC and localization endpoints for this specific compatibility evaluation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Reported sensitivity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-05

No sensitivity value with complete endpoint context was abstracted.

Reported specificity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-05

No specificity value with complete endpoint context was abstracted.

Mammogram-level AUC

0.894 AUC

  • EndpointStandalone discrimination in paired DBT compatibility evaluation
  • Population1,475 patients / 2,950 paired Hologic Dimensions and Envision DBT studies
  • Tested versionMammoScreen 4

MammoScreen 4 Hologic Envision compatibility clinical evaluation

  • DesignMRMC and standalone retrospective evaluation of paired acquisitions.
  • Population1,475 patients with 2,950 paired DBT studies.
  • Scopeexact submission
  • Tested versionMammoScreen 4
  • Samplen=1475
  • IndependenceIndependence not established

K243679

Reference labels include biopsy-positive and benign/negative follow-up categories as described in the summary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Compatible FFDM or DBT screening exams; the cleared modification adds Hologic Envision support.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-05 · MammoScreen 4: K243679 clearance and 510(k) summary

  2. Routing

    Source context, not route validation: Current family documentation describes a site gateway, DICOM output, and optional HL7/FHIR reporting integration.

    Scope: Product family. Not an exact-version interface guarantee.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-06 · MammoScreen integration

  3. AI processing

    Source context, not route validation: Current family documentation describes cloud computation through a site gateway and an on-premises option on request.

    Scope: Product family.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-06 · MammoScreen integration

  4. Returned objects

    Source context, not route validation: Finding marks and finding-, breast- and case-level scores; dedicated user interface/viewer, DICOM Secondary Capture and DICOM Structured Report outputs.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-05 · MammoScreen 4: K243679 clearance and 510(k) summary

  5. Viewer/worklist/report

    Unresolved route: Finding marks and finding-, breast- and case-level scores; dedicated user interface/viewer, DICOM Secondary Capture and DICOM Structured Report outputs.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-05 · MammoScreen 4: K243679 clearance and 510(k) summary

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Current family documentation describes cloud computation through a site gateway and an on-premises option on request.
  • Product family
  • Checked 2026-09-06
Integration
Current family documentation describes a site gateway, DICOM output, and optional HL7/FHIR reporting integration.
  • Product family
  • Checked 2026-09-06

Not an exact-version interface guarantee.

Security
Therapixel's own page says Therapixel and its operations for MammoScreen are ISO/IEC 27001 certified by an independent certification body. The page gives no certificate number, scope statement, issue date or expiry, and the certificate was not read.
  • Vendor-wide
  • Checked 2026-10-25

Vendor-wide statement, not an independent attestation. It does not establish certificate or report scope for this exact release, expiry, data location, retention, identity and access, or incident-response terms for a deployed configuration. Obtain these from the vendor.

Training
The vendor offers remote-installation and training during a limited-time pilot.
  • Product family
  • Checked 2026-09-06

Family gateway workflow

Gateway-based processing with DICOM output and optional reporting-system integration.

product family · checked 2026-09-06
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K243679
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Mammography/DBT
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Anatomy
Breast
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-07-03
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Documented product family

Related FDA records

These links identify a sourced product-family relationship. They do not transfer evidence, metrics, clearance scope, compatibility, pricing, or availability between submissions.

MammoScreen reading aid

Open the documented family

A partial mapping of MammoScreen 4 and 5 reading-aid records. Density products and other releases are not included in this mapping.

Therapixel identifies MammoScreen as its screening-mammography reading software. The manufacturer-prepared K260714 summary explicitly identifies K243679 as MammoScreen 4 and describes both as software versions of MammoScreen. This does not transfer tested input scenarios, evidence, licenses or availability between records.

Mapped FDA decisions, earliest first

Latest mapped does not mean latest sold or installed. Choose an exact FDA record before comparing.

  1. This FDA recordMammoScreen® (4) (K243679)

    MammoScreen 4 reviewed in K243679

    FDA decision: 2025-07-03 · record reviewed 2026-11-05
  2. Related FDA recordMammoScreen® (5) (K260714)

    MammoScreen 5 reviewed in K260714

    Latest mapped FDA decisionFDA decision: 2026-06-26 · record reviewed 2026-11-05
Latest FDA decision among these records
K260714 · 2026-06-26. Latest decision among these mapped records only. This is not a current installed-version or supersession claim.
Latest documented release
The sources do not establish a complete current commercial release chronology.
Current commercial availability
Availability of an exact release and licensed configuration must be confirmed with the supplier.

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-06Last searched
23Fields reviewed
11Source classes checked
1Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

Stored PMID 32159424 is an online breast-cancer risk decision-aid study, not MammoScreen evidence; excluded by metadata. No trial records stored. The current discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, vendor technical page, vendor product page, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-06 - Exact product version

    No public price was located in reviewed vendor material.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "Therapixel MammoScreen reimbursement CPT coverage"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. Therapixel's adoption page describes general US screening mammography policy; it states no coding or payment for this product. This records what was found, not that none exists; eligibility depends on payer, site of service and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Monitoring: Not verified - checked 2026-10-27 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

12 sources - 3 history items

Source ledger

  1. K243679 FDA decision source

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, purpose, modality, anatomy

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. MammoScreen 4 model card (K243679)

    American College of Radiology - Published 2026-07-08 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, evidenceSummary, anatomy, evidenceStudies

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. MammoScreen 5: K260714 clearance and 510(k) summary

    US Food and Drug Administration - Accessed 2026-09-05

    Scope: identity, clinical, implementation, evidence, product_family

  8. MammoScreen integration

    Therapixel / MammoScreen - Accessed 2026-09-06

    Scope: product_family_implementation

  9. Try MammoScreen

    Therapixel / MammoScreen - Accessed 2026-09-06

    Scope: product_family_training

  10. MammoScreen 4: K243679 clearance and 510(k) summary

    US Food and Drug Administration - Accessed 2026-09-05

    Scope: identity, clinical, implementation, evidence

  11. Therapixel is now ISO/IEC 27001 certified

    Therapixel - Accessed 2026-10-25

    Scope: security

  12. MammoScreen by Therapixel: product identity

    Therapixel / MammoScreen - Accessed 2026-11-05

    Scope: product_family

Research history

  1. K243679 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K260714

MammoScreen® (5)

Therapixel

Authorized purpose: Flags calcifications, masses, asymmetries and architectural distortions on compatible FFDM or DBT screening examinations; management must not be based solely on MammoScreen output.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-06-26
FDA-cleared K253825

Saige-Dx

DeepHealth, Inc.

Authorized purpose: Concurrent detection and characterization support for screening DBT mammography

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-06-15
FDA-cleared K252954

MammoSightAI

Neurocareai, Inc. (Dba Savelife.Ai)

Authorized purpose: Tags screening cases as suspicious or blank to aid worklist prioritization; radiologists must review every examination and it does not mark original images.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-05-04
FDA-cleared K260320

Lunit INSIGHT MMG (v1.1.10)

Lunit, Inc.

Authorized purpose: Lunit INSIGHT MMG v1.1.10 aids physicians in detection, localization and characterization of suspicious breast-cancer areas on female screening mammograms from compatible FFDM systems, viewed after the physician's initial read as an adjunct to complete clinical interpretation.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-04-23

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history